Background: Indacaterol is a once-daily, long-acting b 2 -agonist bronchodilator that improves dyspnoea and health status in patients with moderate-to-severe COPD. While its bronchodilator effects have been shown to be maintained in different patient subgroups, effects on clinical outcomes in certain subgroups are not yet defined. Methods: Post-hoc analysis of pooled clinical study data to investigate efficacy and safety of indacaterol compared with placebo and other long-acting bronchodilators (formoterol, salmeterol, open-label tiotropium) in patient subgroups defined by COPD severity (GOLD stage II or III; n Z 4082) and ICS use at baseline (no/yes; n Z 4088). Efficacy outcomes were trough (24-h post-dose) FEV 1 , dyspnoea (transition dyspnoea index; TDI) and health status (St George's Respiratory Questionnaire; SGRQ) after 26 weeks. Results: All active treatments significantly improved trough FEV 1 and dyspnoea compared with placebo, and all apart from open-label tiotropium improved health status compared with placebo. Among active treatments, indacaterol 150 mg had the best overall efficacy profile in the GOLD II and no-ICS subgroups. In the GOLD III and ICS subgroups, indacaterol 300 mg had the best overall efficacy, including a marked effect on dyspnoea (1.4-point improvement in TDI total score vs. placebo; p < 0.001). Within subgroups, the incidence of adverse events was similar between treatments. Conclusion: Indacaterol maintained its efficacy regardless of disease severity or use of concurrent ICS. Indacaterol 150 mg had the best overall efficacy profile in the GOLD stage II patients while, in patients with more severe disease, indacaterol 300 mg provided useful improvements in dyspnoea. ª
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Introduction
Inhaled long-acting bronchodilators feature prominently among the recommended pharmacological treatments for the management of patients with chronic obstructive pulmonary disease (COPD). 1 Available long-acting bronchodilators include the twice-daily long-acting b 2 -agonists (LABAs) formoterol and salmeterol, the once-daily longacting antimuscarinic (LAMA) tiotropium and, more recently, the once-daily LABA indacaterol.
In placebo-controlled clinical studies, indacaterol has demonstrated beneficial effects on lung function, symptoms and health status in patients with moderate-to-severe COPD. 2e5 Most of the clinical trials with indacaterol have included broadly similar proportions of patients with moderate and severe COPD and similar proportions of patients receiving concomitant inhaled corticosteroids (ICS) or not at baseline. Many of the pivotal placebo-controlled studies with indacaterol included pre-specified analyses of the primary efficacy outcome (trough FEV 1 after 12 weeks of treatment) in patient subgroups defined according to factors such as COPD severity, use of ICS, age and smoking status. Adverse event data were also summarised for the subgroups. The results showed that indacaterol maintained a significant bronchodilator effect 3, 4 and a similar level of adverse events in these subgroups. We report here on the results of a posthoc analysis conducted with the aim of exploring further the effects of indacaterol in patient subgroups defined according to COPD severity and ICS use at baseline, evaluating both bronchodilator effects and clinical outcomes (dyspnoea and health status) over a treatment period of 6 months. The analysis was performed using data from more than 4000 patients pooled from three pivotal clinical studies that included comparisons with the other available long-acting inhaled bronchodilators: tiotropium, salmeterol and formoterol, all of which have been published individually. 
Methods

Patients
The studies enrolled men and women aged !40 years with a diagnosis of moderate-to-severe COPD (post-bronchodilator FEV 1 <80% and !30% predicted and FEV 1 /FVC <70%; GOLD 2005 criteria), with a smoking history of !20 packyears. Patients with a recent respiratory tract infection or COPD exacerbation were not included. Concomitant ICS use was allowed but the dose and regimen had to remain stable for the duration of each study. Patients who were receiving LABA/ICS fixed-dose combinations prior to the study were switched to equivalent ICS monotherapy. Patients were allowed to use short-acting b 2 -agonists for symptom relief as needed during the studies.
Study design
Data were pooled from three randomised, double-blind, placebo-controlled studies. Full details of the individual studies have been published previously. 3e5 The first was a 6 month study (NCT00567996) comparing indacaterol 150 mg once daily with placebo and salmeterol 50 mg twice daily, all given double-blind. 5 The second was a 1 year study (NCT00393458) comparing indacaterol 300 mg once daily with placebo and formoterol 12 mg twice daily, all given double-blind (6 month data were included in the present analysis). 3 The third was a 6 month study (NCT00463567) comparing indacaterol 150 mg and 300 mg with placebo (double-blind) and open-label tiotropium 18 mg, once daily. 4 The primary efficacy variable in each of those studies was forced expiratory volume in 1 s (FEV 1 ) at 'trough' (24 h following the previous morning dose of indacaterol or tiotropium and 12 h following the previous evening dose of formoterol or salmeterol) after 12 weeks' treatment.
Assessments and variables
In the present analysis, efficacy was assessed after 26 weeks' treatment. Using standardised spirometry, 6 the bronchodilator effect was measured as trough FEV 1 . Dyspnoea was measured as transition dyspnoea index (TDI) total score and the percentage of patients responding with a minimum clinically important difference (MCID; improvement of !1 point) in TDI total score, with associated odds ratios.
7e9 Health status was measured using St George's Respiratory Questionnaire (SGRQ) total score and the percentage of patients responding with the MCID of !4 units in SGRQ total score, with associated odds ratios. 10, 11 Adverse events were recorded and summarised.
Statistical analysis
Patients were divided into subgroups of GOLD stages II and III, irrespective of ICS use, and into subgroups according to ICS use, irrespective of GOLD stages. In each subgroup (GOLD stages and ICS use) we performed separate statistical analyses.
Trough FEV 1 after 26 weeks of treatment was analysed using a mixed-model analysis of covariance with treatment as a fixed effect and baseline FEV 1 and baseline FEV 1 reversibility (to salbutamol and to ipratropium) as covariates. The same model (with appropriate covariates) was used to analyse the TDI and SGRQ efficacy variables. Missing TDI and SGRQ data were imputed with the last observation (provided this was within the last 11 weeks) carried forward. No powering or sample size calculations were performed for this post-hoc analysis, although all studies were powered individually on the primary efficacy variable described above. Additionally, one of the studies 5 was powered on SGRQ after 12 weeks of treatment. No adjustment was made for multiplicity in the present analyses. Differences between treatment groups are presented as least squares mean values with associated 95% CI.
Results
Patients
Data were available for 4082 patients with information on GOLD severity stage and 4088 patients with information on baseline ICS use. The difference is due to missing screening data on lung function and therefore on COPD severity. In the population defined by ICS use, 56% of patients had no ICS use at baseline ('no-ICS') and 44% of patients had baseline ICS use ('ICS'). Among the latter ICS patients, 52% had GOLD stage II disease. In the population defined by GOLD stage, 58% of patients had COPD at stages II and 42% had COPD at stages III. These two groups contained a small proportion of patients with COPD at GOLD stage I (3.9% of the total population) and stage IV (1.0% of the total population). The reasons for this were a protocol change early in one of the studies to use postbronchodilator (rather than pre-bronchodilator) spirometry when screening for inclusion criteria, and that some patients had borderline spirometry measurements that shifted from GOLD II to I and from GOLD III to IV when values were centrally re-calculated and adjusted for ethnicity in the pooling exercise. These patients were retained in the analysis and the two groups are referred to here as GOLD III and GOLD IV. Overall, 40% of patients with GOLD II stage disease and 50% of patients with GOLD III stage disease were receiving ICS (Table 1) . Baseline data are shown in Table 2 .
Patients with GOLD III stage disease were characterised by lower (worse) dyspnoea scores, higher (worse) health status scores and, in general, a larger proportion of patients with exacerbations in the preceding 12 months compared with patients with GOLD II stage disease (Table 2) . ICS patients were characterised by a longer duration of COPD, a larger proportion of ex-smokers and, in general, a larger proportion of patients with exacerbations within the previous 12 months compared with no-ICS patients (Table 2) .
There were no major imbalances at baseline between treatment groups.
Six-month completion rates are shown in Table 3 . Completion rates were lower with placebo than with active treatments in all subgroups, and activeeplacebo differences were generally more marked in the subgroups with more severe disease and those on ICS.
Patients with GOLD II stage disease severity
Results for trough FEV 1 , TDI total score and SGRQ total score are summarised in Fig. 1 . The two indacaterol doses were not significantly different from each other and were, variously, significantly more effective than formoterol, salmeterol and open-label tiotropium (trough FEV 1 ), formoterol (TDI) and open-label tiotropium (SGRQ). The twicedaily LABAs and open-label tiotropium were not significantly different from each other. The effects of indacaterol were above the MCID for all outcomes apart from the effect of the 300 mg dose on SGRQ (at À3.9, just outside the À4.0 unit threshold). The patterns of treatment effects on TDI and SGRQ scores were similar to the rates of responding (MCID) patients for these outcomes (Table 4) 
Patients with GOLD III stage disease severity
In this subgroup ( Fig. 1) , both indacaterol doses performed better than the twice-daily LABAs in terms of trough FEV 1 , and the 300 mg dose was better than indacaterol 150 mg and open-label tiotropium in its effect on TDI. There was no significant difference between any active treatments for SGRQ, although only indacaterol 150 mg and salmeterol exceeded the MCID, and (as in the other three subgroups) open-label tiotropium was not significantly more effective than placebo. The TDI and SGRQ MCID responder rates (Table 4) also demonstrated the greater effect of indacaterol 300 mg compared with indacaterol 150 mg and open-label tiotropium on TDI. Raw mean changes from baseline in SGRQ total score were À2.1 for placebo-treated patients, À3.5 for open-label tiotropium, À4.5 for formoterol, À4.9 for salmeterol, and À6.6 and À5.2 for indacaterol 150 mg and 300 mg treatments, respectively.
Patients not on ICS
In this subgroup, the two doses of indacaterol were similarly significantly more effective in terms of bronchodilation than the twice-daily LABAs, and were the only Figure 1 Effect of treatments (activeeplacebo differences) on trough FEV 1 , TDI total score and SGRQ total score after 26 weeks of treatment in the four subgroups of patients. The shaded area bounds the MCID for trough FEV 1 (120 mL), TDI total score (þ1) and SGRQ total score (À4.0); effects outside the shaded area are >MCID. All activeeplacebo differences statistically significant (p < 0.05) apart from effect of tiotropium on SGRQ in all subgroups. Other significant (p < 0. treatments to exceed the MCID for TDI (Fig. 1) . Odds ratios for achieving the MCID in TDI were significantly greater with indacaterol compared with open-label tiotropium (both doses) and salmeterol (indacaterol 300 mg) ( Table 4) . Indacaterol 150 mg improved SGRQ by more than the MCID and was significantly more effective than formoterol, openlabel tiotropium and indacaterol 300 mg (Fig. 1) . Odds ratios for achieving the SGRQ MCID were significantly higher with indacaterol 150 mg than formoterol and open-label tiotropium, while the effect of salmeterol did not differ significantly from placebo (Table 4) .
Patients on ICS
Indacaterol had a greater effect on trough FEV 1 than the twice-daily LABAs (both doses) and open-label tiotropium (150 mg dose only); the 300 mg dose had a significantly greater effect than the 150 mg dose (Fig. 1) . The 300 mg dose was significantly more effective than formoterol and the lower dose of indacaterol in its effect on TDI ( Fig. 1) and had a significantly higher odds ratio for achieving the MCID in TDI than open-label tiotropium (Table 4) , and narrowly failed to achieve the MCID for SGRQ (À3.6 units vs. placebo).
The effects of all the b 2 -agonists on SGRQ were clustered closely around the MCID, but only salmeterol exceeded the MCID (À4.1 vs. placebo). However, the odds ratio for achieving the MCID in SGRQ with salmeterol did not differ significantly from placebo (Table 4) . Table 5 presents the overall incidence of adverse events and those most commonly occurring in each of the subgroups. Within each of the subgroups, the overall incidence of adverse events was numerically highest with Table 4 Percentages of patients achieving the MCID and associated odds ratios (95% CI) vs. placebo for TDI total score (!1 point) and for SGRQ total score (!À4 units). Odds ratios for all significant differences between active treatments are included. *p < 0.05; **p < 0.01; ***p < 0.001. open-label tiotropium and lowest with salmeterol compared with placebo and with the other active treatments, where the incidence was similar. In all subgroups and treatment groups, the commonest adverse events were those affecting the respiratory tract. Comparing the subgroups, the incidence of COPD worsening was higher in the GOLD III subgroup than in the GOLD II subgroup, and higher in the patients receiving ICS than in those who were not. 
Safety
GOLD
Discussion
The present analysis enables us to evaluate the relative efficacy of inhaled long-acting bronchodilators in terms of both bronchodilator effect and the clinical outcomes of dyspnoea and health status in different populations of patients with COPD, over a period of time that is long enough to be relevant to clinical practice. Comparing the two disease severity subgroups, treatment effects were generally larger in the GOLD II patients than in the GOLD III patients. Similar findings were observed in the subgroup analyses from the large, long-term UPLIFT 12 and TORCH 13 studies, which demonstrated the benefits of treating patients with GOLD stage II disease. This has important implications for early treatment of COPD, especially as recent studies have shown that patients with moderate disease may experience a more rapid decline in lung function than those with more severe disease.
14e16
Considering the effects of treatment on the outcomes assessed in the present analysis, we would judge indacaterol 150 mg to be the most effective treatment for those patients with GOLD stage II disease, not only as a bronchodilator but also in terms of improvement in dyspnoea and health status, with all improvements exceeding the threshold for a clinically relevant effect. Compared with open-label tiotropium, a widely used bronchodilator in COPD, indacaterol 150 mg was significantly more effective at improving health status. A similar pattern of treatment effect was observed in patients in the no-ICS subgroup, which overlapped to a large extent with the GOLD II subgroup. There was little difference between the effects of the two doses of indacaterol in patients in the GOLD II and no-ICS subgroups. However, it was interesting to observe that in the GOLD III and ICS subgroups (again, with a large degree of overlap) it was the 300 mg dose of indacaterol that appeared to have the best overall profile of efficacy, and was significantly more effective than the 150 mg dose in its effect on dyspnoea. These improvements in dyspnoea are particularly important, since breathlessness is the most disabling symptom for COPD patients. 17, 18 In a recently published survey of 1084 COPD patients receiving monotherapy with a long-acting bronchodilator (tiotropium was used by 76%, formoterol by 14% and salmeterol by 9%), many patients had poor health status and experienced significant symptoms, and those with more severe disease had worse dyspnoea. 19 It appears that there is a therapeutic need for a more effective long-acting bronchodilator, and the 300 mg dose of indacaterol may be a particularly useful option for patients with severe dyspnoea. Renard and colleagues 20 modelled the relationship between indacaterol dose and bronchodilator response (steady-state trough FEV 1 ) using data from placebocontrolled studies of at least 14 days in duration in patients with COPD, and found a clinically relevant bronchodilator effect (difference of !120 mL vs. placebo) with doses of 75 mg once daily and higher. When the bronchodilator dose-response was modelled according to disease severity, patients with moderate COPD were predicted to have a steeper dose-response with a larger maximum response, whereas patients with severe COPD had a shallower dose response with a lower maximum response. Thus, compared with those with moderate COPD, the doseresponse plateau is reached at higher doses in patients with severe COPD such that the higher doses would have a relatively greater impact, which was reflected in the greater separation of effect between the 150 and 300 mg doses in the severe subgroup in the present analysis. 20 An indacaterol dose of 75 mg once daily is the only approved dose for use in the USA and Canada, but did not form part of the studies from which the present population was drawn. Those two countries approved the lower of two indacaterol doses submitted for evaluation (75 and 150 mg) on the basis that indacaterol 75 mg was judged to be the minimally effective dose. However, both doses were considered to have an adequate safety profile. 21 A dose of 600 mg (not approved for use in any country) was evaluated over 1 year and was reported to be well tolerated. 3 The GOLD stages in the present analysis reflect the level of airflow limitation, which at the time of enrolment into the studies was how GOLD classified overall COPD severity, with treatment recommendations for each severity stage. GOLD now uses this staging to classify airflow limitation and makes treatment recommendations according to symptoms (assessed by the modified Medical Research Council or COPD Assessment Test instruments) and patient risk, which depends on a combination of severity of airflow limitation (GOLD IeIV) and exacerbation history. 1 Following GOLD guidelines, highrisk patients as defined by GOLD IIIeIV or repeated exacerbations 1, 22 would be treated with ICS. Interestingly, in this pooled analysis only 9% of patients classified as GOLD III had a COPD exacerbation in the 12 months prior to entering the studies, yet 50% of them were on concomitant ICS. However, patients in the GOLD III and ICS subgroups had a notably higher incidence of COPD worsening as an adverse event, a definition that would have encompassed a range from worsening symptoms to exacerbations of COPD, which may provide a reason for the ICS use. Baseline data also showed that 35% of patients with GOLD II COPD were treated with ICS and, although our data are insufficient to know if some of the GOLD II patients were receiving ICS for repeated exacerbations, only 5% had reported an exacerbation in the previous year. Patients with a history of asthma were not enrolled in the indacaterol studies, so it is very unlikely that the ICS were being given for mixeddisease asthma and COPD. Baseline reversibility was comparable between ICS and non-ICS groups and should therefore not have been an underlying factor in ICS use.
A high level of ICS in patients with moderate COPD has been reported elsewhere. 23e28 The potential over-use of ICS may be of concern, since the higher risk:benefit ratio associated with the use of ICS in COPD than in asthma suggests that these agents should be administered within GOLD guideline recommendations. 29, 30 Arguably the most concerning side-effect of ICS in COPD is the increased risk of pneumonia, 31e35 which may be reflected in the increased incidence of lower RTI in the ICS-using patients in the present analysis. Although the incidence of pneumonia was similar between no-ICS and ICS subgroups, cases of pneumonia may have been included in the category of LRTI. Radiographic confirmation of pneumonia or LRTI was not routinely obtained in the studies contributing to the present analysis.
Finally, it is important to note that there were a number of limitations in this post-hoc analysis. Analysis of subgroups such as these results in small patient numbers, particularly in the active comparator groups (data for openlabel tiotropium, formoterol and salmeterol came from a single study each), where results may need to be interpreted with caution owing to a relative lack of power to detect differences. The highest patient numbers were in the indacaterol and placebo treatment groups, and these provide the most robust comparisons. Furthermore, the open-label administration of tiotropium 4 also raises the possibility that results were biased in one direction or the other, particularly for the more subjective outcome measures. In addition, none of the variables in this analysis was a primary outcome in the three source studies, although one of those studies was powered to detect indacateroleplacebo differences in SGRQ. 5 Another, more general consideration in drug trials in COPD is that the difference between active and placebo treatments for SGRQ is usually influenced by improvement in SGRQ scores in the placebo group, due to two factors. One is the 'trial' effect on medication intake in the placebo group, which (as shown here by the change from baseline data) is likely to be larger in patients with less severe COPD. The second is the higher drop-out rate from placebo compared with active treatments, which, as we observed, is likely to be more prominent in patients with more severe COPD compared with those with milder disease.
Conclusion
Indacaterol maintained its efficacy with a good profile of tolerability regardless of COPD severity or concurrent ICS use. Indacaterol would be an appropriate initial maintenance therapy for patients with COPD. In patients with more severe disease (GOLD stages III), the 300 mg dose of indacaterol may provide additional control of dyspnoea.
